Provided by Tiger Fintech (Singapore) Pte. Ltd.

Inhibikase Therapeutics, Inc.

1.67
+0.01000.60%
Volume:26.60K
Turnover:44.27K
Market Cap:124.15M
PE:-2.03
High:1.67
Open:1.66
Low:1.66
Close:1.66
Loading ...

Press Release: Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity

Dow Jones
·
28 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
27 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
24 Mar

Inhibikase Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview

Reuters
·
21 Mar

Inhibikase Therapeutics (IKT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Zacks
·
05 Mar

Inhibikase Announces Expansion of Senior Leadership Team

THOMSON REUTERS
·
24 Feb

Inhibikase Announces Expansion of Senior Leadership Team

GlobeNewswire
·
24 Feb

Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Company’s Growth

THOMSON REUTERS
·
18 Feb

HC Wainwright Downgrades Inhibikase Therapeutics to Neutral From Buy

MT Newswires Live
·
12 Feb

Inhibikase Therapeutics, Inc. : H.c. Wainwright Cuts to Neutral From Buy

THOMSON REUTERS
·
12 Feb

Insiders Enjoy US$1.1m Return After Buying Inhibikase Therapeutics Stock

Simply Wall St.
·
31 Jan

Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study

Reuters
·
30 Jan

BRIEF-Inhibikase Therapeutics Inc Says 201 Trial Met Primary Endpoint Of Safety And Tolerability

Reuters
·
30 Jan

Inhibikase Therapeutics Inc - Risvodetinib Treatment Did Not Show Improvement in Top Hierarchical Efficacy Measure

THOMSON REUTERS
·
30 Jan

Inhibikase Therapeutics Inc - 201 Trial Met Primary Endpoint of Safety and Tolerability

THOMSON REUTERS
·
30 Jan

Bullish Inhibikase Therapeutics Insiders Loaded Up On US$2.70m Of Stock

Simply Wall St.
·
21 Jan